Neurogene, Inc. - Common Stock NGNE 深 滬
等待開盤 12-13 09:30:00 美东时间
20.92
-0.340
-1.60%
華盛通- 最 高21.75
- 今 開21.25
- 成交量 14.44万股
- 最 低 20.88
- 昨 收 21.26
- 總市值 2.99亿
- 52周最高 37.2659
- 市盈率 靜 --
- 換手率 1.01%
- 52周最低 6.875
- 委 比 -5.26%
- 總股本 1427.19万
- 歷史最高 362.60
- 量 比 0.95
- 振 幅 4.09%
- 歷史最低 6.875
- 每 手 1
- 風險率 5.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Neurogene Announces Updated Interim Clinical Study In Pediatric Group From Its Current Phase 1/2 Trial Evaluating NGN-401 Demonstrates All 8 Patients Showed Functional Gains Across Spectrum Of Disease Severity
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive, updated interim clinical
11-13 05:13
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
11-05 03:25
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $65
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $45 to $65.
10-31 18:58
正极材料周报丨蔚蓝锂芯拟增资格林美印尼项目！又一材料公司破产重整！
（来源：我的电池网） 【编者按】正极材料周报，系电池网（微号：mybattery）与国内知名企业容百控股下辖公司——容百科技（微号：Ronbay6880...
10-20 16:12
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 81.2% to $3....
10-10 01:06
Neurogene Completes Discussions With FDA On Embolden Trial, Plans To Initiate Dosing In Q4 2025 Across 13 Rett Syndrome Sites
Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollmentNew preclinical data at ESGCT Congress highlight NGN-401 best-in-class potential and add to body of evidence that ICV
10-09 19:08
4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be rapidly gaining strength.
10-07 23:19
